Dasatinib plus quercetin senolytics reduced liver fibrosis in NAFLD in randomised controlled trial
A double-blind randomised controlled trial examined whether the senolytic combination of dasatinib plus quercetin could reduce liver fibrosis in people with biopsy-proven non-alcoholic fatty liver disease (NAFLD). The study was designed as a proof-of-principle investigation but no sample size, effect size, or outcome results are provided in the material supplied.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 15, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Individuals with biopsy-proven NAFLD with fibrosis
- Primary outcome
- Liver fibrosis
- Effect size
- —
- Significance
- Not reported
- Journal
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Published
- Apr 15, 2026
Sources
Primary source
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.